This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Molecular Templates Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Craig Jalbert

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	geen gegevens

Recente managementupdates

Recent updates

Analyseartikel • Oct 10

There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 30% Share Price Rise

Molecular Templates, Inc. ( NASDAQ:MTEM ) shares have had a really impressive month, gaining 30% after a shaky period...

Analyseartikel • Aug 17

Earnings Release: Here's Why Analysts Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Price Target To US$18.00

Molecular Templates, Inc. ( NASDAQ:MTEM ) just released its latest second-quarter report and things are not looking...

Analyseartikel • Jul 30

Molecular Templates, Inc.'s (NASDAQ:MTEM) Shares Bounce 27% But Its Business Still Trails The Industry

Those holding Molecular Templates, Inc. ( NASDAQ:MTEM ) shares would be relieved that the share price has rebounded 27...

Analyseartikel • Apr 03

Little Excitement Around Molecular Templates, Inc.'s (NASDAQ:MTEM) Revenues As Shares Take 48% Pounding

Molecular Templates, Inc. ( NASDAQ:MTEM ) shareholders that were waiting for something to happen have been dealt a blow...

Analyseartikel • Dec 20

Lacklustre Performance Is Driving Molecular Templates, Inc.'s (NASDAQ:MTEM) 26% Price Drop

Unfortunately for some shareholders, the Molecular Templates, Inc. ( NASDAQ:MTEM ) share price has dived 26% in the...

Analyseartikel • Apr 17

There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 45% Share Price Rise

Molecular Templates, Inc. ( NASDAQ:MTEM ) shares have had a really impressive month, gaining 45% after a shaky period...

Analyseartikel • Nov 16

What Does The Future Hold For Molecular Templates, Inc. (NASDAQ:MTEM)? These Analysts Have Been Cutting Their Estimates

Market forces rained on the parade of Molecular Templates, Inc. ( NASDAQ:MTEM ) shareholders today, when the analysts...

Analyseartikel • Aug 14

Time To Worry? Analysts Are Downgrading Their Molecular Templates, Inc. (NASDAQ:MTEM) Outlook

The latest analyst coverage could presage a bad day for Molecular Templates, Inc. ( NASDAQ:MTEM ), with the analysts...

Seeking Alpha • Aug 11

Molecular Templates GAAP EPS of -$0.44 misses by $0.01, revenue of $4.42M misses by $2.6M

Molecular Templates press release (NASDAQ:MTEM): Q2 GAAP EPS of -$0.44 misses by $0.01. Revenue of $4.42M (-70.8% Y/Y) misses by $2.6M. As of June 30, 2022, MTEM’s cash and investments totaled $104.4M. MTEM’s current cash and investments are expected to fund operations to the end of 2023.

Analyseartikel • Apr 29

Rock star Growth Puts Molecular Templates (NASDAQ:MTEM) In A Position To Use Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Analyseartikel • Dec 30

Health Check: How Prudently Does Molecular Templates (NASDAQ:MTEM) Use Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Analyseartikel • Nov 25

Some Analysts Just Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates

One thing we could say about the analysts on Molecular Templates, Inc. ( NASDAQ:MTEM ) - they aren't optimistic, having...

CEO

Craig Jalbert

no data

Tenure

Craig Jalbert is President, Chief Executive Officer and Chief Financial Officer of Molecular Templates, Inc.

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2025/07/21 02:50
Aandelenkoers aan het einde van de dag	2025/07/21 00:00
Inkomsten	2024/06/30
Jaarlijkse inkomsten	2023/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Molecular Templates, Inc. wordt gevolgd door 8 analisten. 0 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Carter Gould	Barclays
Tazeen Ahmad	BofA Global Research
Roger Song	Jefferies LLC

This company listing is no longer active

Molecular Templates Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Molecular Templates, Inc. Announces Chief Financial Officer Changes

Molecular Templates, Inc., Annual General Meeting, Sep 27, 2024

Molecular Templates, Inc. Announces Cessation of Maurizio Voi as Chief Medical Officer, Effective April 30, 2024

Molecular Templates, Inc. Announces Board Changes

Molecular Templates, Inc. Announces Chief Medical Officer Changes, Effective as of October 2, 2023

Molecular Templates, Inc., Annual General Meeting, Oct 27, 2023

Recent updates

Molecular Templates, Inc. announced that it expects to receive $250 million in funding

Interim DIP Financing Approved for Molecular Templates, Inc.

Motion for Joint Administration Approved for Molecular Templates, Inc.

Molecular Templates, Inc. Filed for Bankruptcy

Molecular Templates, Inc.(NasdaqCM:MTEM) dropped from S&P TMI Index

Molecular Templates, Inc.(OTCPK:MTEM) dropped from NASDAQ Composite Index

Molecular Templates, Inc. Provides Nasdaq Non-Compliance Update

Molecular Templates, Inc. Announces Chief Financial Officer Changes

Molecular Templates Receives Non-Compliance Letters from Nasdaq

Molecular Templates, Inc. announced delayed 10-Q filing

There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 30% Share Price Rise

Consensus EPS estimates upgraded to US$2.90 loss, revenue downgraded

Earnings Release: Here's Why Analysts Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Price Target To US$18.00

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Molecular Templates, Inc., Annual General Meeting, Sep 27, 2024

Molecular Templates, Inc.'s (NASDAQ:MTEM) Shares Bounce 27% But Its Business Still Trails The Industry

New major risk - Share price stability

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Shareholder dilution

Molecular Templates, Inc. Announces Cessation of Maurizio Voi as Chief Medical Officer, Effective April 30, 2024

Molecular Templates, Inc. Presents Interim Data from Mt-6402 Phase I Study in Patients with Pd-L1+ Solid Tumors At the 2024 American Association for Cancer Research Annual Meeting

Consensus revenue estimates decrease by 44%, EPS upgraded

Little Excitement Around Molecular Templates, Inc.'s (NASDAQ:MTEM) Revenues As Shares Take 48% Pounding

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Market cap size

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Molecular Templates, Inc. Announces Board Changes

Lacklustre Performance Is Driving Molecular Templates, Inc.'s (NASDAQ:MTEM) 26% Price Drop

Consensus revenue estimates increase by 16%

New major risk - Financial position

Molecular Templates, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors

Molecular Templates, Inc. Announces Chief Medical Officer Changes, Effective as of October 2, 2023

Molecular Templates, Inc., Annual General Meeting, Oct 27, 2023

New major risk - Revenue and earnings growth

Molecular Templates Announces 1-for-15 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Molecular Templates, Inc. Announces Executive Changes

New minor risk - Shareholder dilution

Molecular Templates, Inc. announced that it expects to receive $40.044 million in funding from BVF Partners L.P., Adage Capital Management, L.P., Bellevue Asset Management AG

New major risk - Financial position

Consensus revenue estimates decrease by 16%, EPS upgraded

Molecular Templates, Inc. Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma

Price target decreased by 67% to US$3.50

Consensus revenue estimates increase by 384%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 45% Share Price Rise

Consensus revenue estimates decrease by 34%, EPS upgraded

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased by 22% to US$10.13

Insufficient new directors

Consensus revenue estimates increase by 13%

What Does The Future Hold For Molecular Templates, Inc. (NASDAQ:MTEM)? These Analysts Have Been Cutting Their Estimates

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased to US$10.13

Time To Worry? Analysts Are Downgrading Their Molecular Templates, Inc. (NASDAQ:MTEM) Outlook

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Molecular Templates GAAP EPS of -$0.44 misses by $0.01, revenue of $4.42M misses by $2.6M

Price target decreased to US$9.33

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Rock star Growth Puts Molecular Templates (NASDAQ:MTEM) In A Position To Use Debt

Price target decreased to US$10.92

Consensus forecasts updated

Price target decreased to US$10.92

Price target decreased to US$11.25

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind